| Mrs Coral Louise Barrilleaux, LCSW | |
|
120 Keawa Street, Suite 204a, Hilo, HI 96720 | |
| (808) 756-2129 | |
| Not Available |
| Full Name | Mrs Coral Louise Barrilleaux |
|---|---|
| Gender | Female |
| Speciality | Social Worker - Clinical |
| Location | 120 Keawa Street, Hilo, Hawaii |
| Accepts Medicare Assignments | Medicare enrolled and may accept medicare through third-party reassignment. May prescribe medicare part D drugs. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1609006485 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 1041C0700X | Social Worker - Clinical | 3576 (Hawaii) | Primary |
| Entity Name | West Hawaii Community Health Center, Inc. |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1952335630 PECOS PAC ID: 1557389400 Enrollment ID: O20051109000287 |
News Archive
Akebia Therapeutics, Inc., a biopharmaceutical company focused on the development of novel proprietary therapeutics based on hypoxia-inducible factor (HIF) biology and the commercialization of these products for patients with kidney disease, today announced it has completed enrollment in its ongoing 200-patient Phase 2b study of AKB-6548 for the treatment of anemia associated with chronic kidney disease (CKD) in patients who are not dependent on dialysis.
Hospital for Special Surgery physician-scientists who focus on arthritis, lupus, vasculitis and related conditions are traveling from New York City to Chicago this week to share their recent findings at the 75th Annual Scientific Meeting of the American College of Rheumatology.
A new study has revealed that men hoping to conceive should stop drinking for at least six months before to prevent congenital heart diseases.
Anyone who has watched an infant's eyes follow a dangling trinket dancing in front of them knows that babies are capable of paying attention with laser focus.
Omeros Corporation today announced additional positive data from its Phase 1 program for OMS824, the lead compound in Omeros' phosphodiesterase 10 (PDE10) program. This clinical trial evaluated the extent to which OMS824 binds to PDE10, an enzyme expressed in the region of the brain that has been linked to a wide range of diseases that affect cognition. In the latest cohort enrolled in this trial, OMS824 achieved a high of approximately 70‑percent engagement at PDE10 without evidence of extrapyramidal symptoms (EPS).
› Verified 7 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Mrs Coral Louise Barrilleaux, LCSW Po Box 6231, Hilo, HI 96720-8924 Ph: (808) 756-2129 | Mrs Coral Louise Barrilleaux, LCSW 120 Keawa Street, Suite 204a, Hilo, HI 96720 Ph: (808) 756-2129 |
News Archive
Akebia Therapeutics, Inc., a biopharmaceutical company focused on the development of novel proprietary therapeutics based on hypoxia-inducible factor (HIF) biology and the commercialization of these products for patients with kidney disease, today announced it has completed enrollment in its ongoing 200-patient Phase 2b study of AKB-6548 for the treatment of anemia associated with chronic kidney disease (CKD) in patients who are not dependent on dialysis.
Hospital for Special Surgery physician-scientists who focus on arthritis, lupus, vasculitis and related conditions are traveling from New York City to Chicago this week to share their recent findings at the 75th Annual Scientific Meeting of the American College of Rheumatology.
A new study has revealed that men hoping to conceive should stop drinking for at least six months before to prevent congenital heart diseases.
Anyone who has watched an infant's eyes follow a dangling trinket dancing in front of them knows that babies are capable of paying attention with laser focus.
Omeros Corporation today announced additional positive data from its Phase 1 program for OMS824, the lead compound in Omeros' phosphodiesterase 10 (PDE10) program. This clinical trial evaluated the extent to which OMS824 binds to PDE10, an enzyme expressed in the region of the brain that has been linked to a wide range of diseases that affect cognition. In the latest cohort enrolled in this trial, OMS824 achieved a high of approximately 70‑percent engagement at PDE10 without evidence of extrapyramidal symptoms (EPS).
› Verified 7 days ago
Howard Timothy Baldwin, LCSW, DCSW Clinical Social Worker Medicare: Medicare Enrolled Practice Location: 213 Ululani St, Hilo, HI 96720 Phone: 808-961-2811 | |
Reginamarie Ching, Clinical Social Worker Medicare: Not Enrolled in Medicare Practice Location: 71 Pohakulani St, Hilo, HI 96720 Phone: 808-959-3515 Fax: 808-981-2915 | |
Laura Dvorak, Clinical Social Worker Medicare: Medicare Enrolled Practice Location: 784 Amauulu Rd, Hilo, HI 96720 Phone: 908-612-9390 | |
Mr. Matthew D Brittain, LCSW Clinical Social Worker Medicare: Not Enrolled in Medicare Practice Location: 56 Waianuenue Ave Ste 207, Hilo, HI 96720 Phone: 808-934-7566 Fax: 808-934-9442 | |
Mr. David Fundakowski, Clinical Social Worker Medicare: Not Enrolled in Medicare Practice Location: 1384 Kinoole St., Hilo, HI 96720 Phone: 808-443-9803 | |
Ms. Priscilla T Lee, LCSW Clinical Social Worker Medicare: Medicare Enrolled Practice Location: 56 Waianuenue Ave Ste 208, Hilo, HI 96720 Phone: 808-969-9211 Fax: 808-969-9211 | |
Sharra Dancel, LCSW Clinical Social Worker Medicare: Not Enrolled in Medicare Practice Location: 305 Wailuku Dr Ste 5, Hilo, HI 96720 Phone: 808-238-0270 Fax: 808-443-0070 |